These data suggest that Ptges inhibitors blocking PGE2 biosynthesis, such as C118 and C934 (ref. 28), which were tested in the current study, as well as EP4 signaling antagonists, may represent good drug candidates for the treatment of prion diseases. Here, PTGER4 is linked to prion disease.